Strides Arcolab shifts focus away from US to Europe

24 Aug 2011 Evaluate

Strides Arcolab, the Bangalore-based manufacturer of IP-led pharma products, especially sterile injectables, has decided to move away from the US market and shift its focus to the European market with plans to file a significant number of products there. The company already has a significant portfolio build-up in the US market.

At the end of second quarter (Q2) of calendar year 2011, the company's cumulative filings and approval in key regulated markets include: 157 dossier filed for the US market (of which approval received is 60), 48 for Europe (9) and 40 for Australia/New Zealand (21).

During the calendar year 2010, the company posted Rs 1,765.5 crore in revenues, of which 15 per cent came from North America, 19 per cent from Europe, 33 per cent from Australasia, 6 per cent from Latin America, 14 per cent Africa and 13 per cent from the rest. The company expects its Q3 to be significant, when many new products are to be launched. Early this year, the company launched only 10 products in the US market.crackcrack

Strides Pharma Scien Share Price

859.00 22.45 (2.68%)
31-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1462.50
Dr. Reddys Lab 5784.50
Cipla 1451.25
Zydus Lifesciences 1001.15
Lupin 1587.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.